The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

Inclusion Criteria:

1. Age ≥ 18 years old;
2. EGFRm NSCLC of local progression (IIIB stage) or metastasis (IV stage);
3. previously confirmed to have EGFR (Ex19del or L858R) mutation, or T790M, received Osimertinib treatment. According to Recist 1.1 imaging findings, the focus progressed slowly and there was no systemic explosive progress (definition of slow progress: disease control \> 6 months, slightly increased tumor load and symptom score ≤ 1);
4. patients who intend to use Furmonertinib (double dose, 160mg) anticancer therapy;
5. At least one tumor lesion in the patient can meet the following requirements: it has not been irradiated in the past and can be accurately measured, the longest diameter of the baseline phase is ≥ 10mm (in the case of lymph nodes, short axis ≥ 15mm is required), and the measurement method can be chest CT or PET-CT, as long as repeated measurements can be completed accurately;
6. No treatable target was found in the second biopsy after drug resistance;
7. The survival time was more than 3 months;

Exclusion Criteria:

1. Patients who have been treated with Furmonertinib;
2. Patients who intend to use anticancer therapy other than Furmonertinib recently;
3. Contraindications for the use of Furmonertinib;